首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   191篇
  免费   11篇
  国内免费   2篇
耳鼻咽喉   3篇
妇产科学   19篇
基础医学   17篇
口腔科学   1篇
临床医学   11篇
内科学   62篇
皮肤病学   8篇
神经病学   8篇
特种医学   7篇
外科学   24篇
预防医学   4篇
眼科学   2篇
药学   3篇
肿瘤学   35篇
  2023年   1篇
  2022年   1篇
  2021年   6篇
  2020年   2篇
  2019年   3篇
  2018年   5篇
  2017年   6篇
  2016年   1篇
  2015年   5篇
  2014年   10篇
  2013年   11篇
  2012年   9篇
  2011年   5篇
  2010年   13篇
  2009年   8篇
  2008年   8篇
  2007年   6篇
  2006年   13篇
  2005年   10篇
  2004年   9篇
  2003年   8篇
  2002年   8篇
  2001年   7篇
  2000年   7篇
  1999年   9篇
  1998年   3篇
  1997年   2篇
  1996年   4篇
  1993年   3篇
  1992年   1篇
  1991年   2篇
  1990年   2篇
  1989年   3篇
  1988年   3篇
  1987年   7篇
  1986年   1篇
  1985年   1篇
  1984年   1篇
排序方式: 共有204条查询结果,搜索用时 15 毫秒
1.
2.
We analyzed in advanced ovarian serous G3 carcinoma the correlation between epidermal growth factor receptor (EGFR) overexpression and tumor angiogenesis and their relation with clinical outcome. Microvessel density (MVD) and vascular endothelial growth factor (VEGF) were statistically correlated with disease-free interval and death from disease both in univariate and multivariate analyses while EGFR expression was not correlated with clinical outcome. MVD was significantly associated with progression of disease during chemotherapy while VEGF and EGFR expression were not correlated with responsiveness to chemotherapy (Fisher's exact test). VEGF expression was correlated with MVD (Fisher's exact test). EGFR showed a trend to correlation with MVD. Further studies focusing on the use of angiogenesis inhibitors in addition to EGFR inhibitors on ovarian carcinoma cells may produce therapeutic strategies in the selection of tailored therapies in ovarian cancer patients.  相似文献   
3.
OBJECTIVE: To compare nasal symptomatology and function and local concentrations of estradiol (E2), estradiol receptor (ERalpha), vasoactive intestinal peptide (VIP), substance P (SP) and neuropeptide Y (NPY) in nasal biopsies of 20 postmenopausal women complaining of paradoxical nasal stuffiness before and after treatment with intranasal or transdermal E2. DESIGN: Twenty healthy postmenopausal women willing to start hormone therapy (HT) were allocated to one of two groups, using a computer-generated randomization list.Ten postmenopausal women were treated with transdermal 17beta-estradiol 50 microg daily plus nomegestrole acetate 5 mg/day for 12 days per 28-day cycle for 6 months (Group A). Ten postmenopausal women were treated with intranasal 17beta-estradiol 300 microg/day (one spray delivery of 150 microg per nostril) plus nomegestrole acetate 5 mg/day for 12 days per 28-day cycle for 6 months (Group B). Fourteen fertile women undergoing nasal mucosa biopsy during plastic surgery were used as controls for the immunohistochemical evaluation (Group C).All women in groups A and B underwent evaluation of nasal stuffiness score, mucociliary transport time, rhinoscopy, and active anterior rhinomanometry at the beginning of the study and after, VIP, SP, and 6 months of HT. Nasal biopsies and evaluation of local concentrations of E2, ERalpha NPY were performed in groups A and B before and after 6 months of HT and in group C. RESULTS: Both intranasal and transdermal HT improve nasal symptomatology and nasal mucosa appearance and reduce mean mucociliary transport time. The effectiveness of intranasally administered therapy at improving nasal function is significantly better than transdermal therapy. In comparison with premenopausal controls, untreated postmenopausal women of group A and B showed significantly decreased immunopositivity for E2, ERalpha, and SP. HT induced a significant increase in E2, ERalpha, VIP, and SP and a decrease in NPY immunopositivity. Intranasal therapy was associated with a significantly higher immunopositivity for VIP and SP. CONCLUSIONS: HT improves nasal function and symptomatology in postmenopausal women with paradoxical nasal stuffiness, modulating nasal mucosa function through an action on cholinergic, adrenergic, and sensory peptides. Intranasally administered HT is more effective at improving nasal function than transdermal HT.  相似文献   
4.
A causal treatment for traumatic Spinal Cord Injury (SCI) is the goal of the charitable Wings for Life Spinal Cord Research Foundation, located in Salzburg. In order realize this ambitioned endeavour, since 2004 Wings for Life competitively funds selected scientific projects aiming at the neurobiological repair of the injured spinal cord.An international Medical/Scientific Board and independent Peer Review Panel composed of more than 200 renowned Scientists and Clinicians (Wings for Life-?Faculty“) specialized on Spinal Cord Injury support the Executive board selecting the most promising projects within a 2 step ?Peer Review“ procedure. To date, Wings for Life funds more than 55 research projects. The projects range from basic science (target finding), applied basic and preclinical research (target validation) to clinical trials.In collaboration with twelve respected, specialized ?non-governmental organisations“ (NGOs), Wings for Life forms the umbrella organisation ICCP (International Campaign for Cures of Spinal Cord Injury) a world-wide network which develops synergies for responsible and effective translational research in spinal cord injury.  相似文献   
5.
BackgroundThymoma is a rare mediastinal neoplasia. Surgery is the backbone of the treatment, but the role of postoperative radiotherapy (PORT) remains controversial. We aimed to obtain data on survival and safety in patients treated with PORT in three different Italian institutions.MethodsWe retrospectively analyzed 183 consecutive patients who underwent surgery from 1981 to 2015. According to the Masaoka-Koga staging system, 39.3%, 32.7%, 18.6% and 9.8% patients were in stage I, II, III and IV of disease, respectively. PORT was indicated in 114 patients (62.3%), while 69 subjects underwent surgery alone. Complete resection was obtained in 68 patients who underwent PORT. Adverse events (AEs) were graded according to CTCAE v4.0. We analyzed the recent literature to describe the current reports on PORT for resected thymoma.ResultsMean follow-up was 130 months (range, 3–417 months). Overall survival (OS) at 1-, 5- and 10-year from surgery was 98.3%, 90.2% and 69.7% respectively. One-, 5- and 10-year disease specific survival (DSS) was 98.9%, 92.3% and 89.8% respectively. Disease free survival (DFS) at 1, 5 and 10 years from surgery was 96.7%, 88.3% and 82.8% respectively. Univariate analysis showed that complete resection, cell histology A-AB-B1 and stages I–II were significant predictors of better DSS and DFS. Multivariate analysis showed that sex, R0 margins and WHO histology was independent prognostic factors. Among patients treated with PORT, a trend towards better OS was evident with Masaoka stage I–II (P=0.09). Patients with R0 margins treated with PORT showed better OS and DSS (P=0.05). No differences in DSS for performance status (P=0.70), WHO histology (P=0.19), paraneoplastic syndrome (P=0.23) and surgical procedure (P=0.53) were evident. Patients treated with PORT had a higher level of acute AEs compared to surgery alone, but none of these was graded ≥3.ConclusionsOur results confirmed that patients with incompletely resected thymoma had the worst OS and DSS. High grade acute toxicity was not different between PORT and surgery alone. Other trials reported a significant benefit in OS, DSS and DFS in stage IIb–IV thymoma treated with PORT.  相似文献   
6.
7.
8.
9.
In its new roadmap for neglected tropical diseases, the World Health Organization proposes three important strategic shifts: (i) Stronger accountability which s...  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号